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Abstract
Background: Pramipexole exists as two isomers. The S(-) enantiomer is a potent D3/D2 receptor agonist and is
extensively used in the management of PD. In contrast, the R(+) enantiomer is virtually devoid of any of the DA
agonist effects. Very limited studies are available to characterize the pharmacological spectrum of the R(+)
enantiomer of pramipexole.
Results: Using differentiated SH-SY5Y neuroblastoma cells as an experimental model, here we show that S(-) and R
(+) pramipexole are endowed with equipotent efficacy in preventing cell death induced by H2O2 and inhibiting
mitochondrial reactive oxygen species generation. Both pramipexole enantiomers prevented mitochondrial ROS
generation with a potency about ten times higher then that elicited for neuroprotection.
Conclusions: These results support the concept of both S(-) and R(+) pramipexole enantiomers as mitochondria-
targeted antioxidants and suggest that the antioxidant, neuroprotective activity of these drugs is independent of
both the chiral 6-propylamino group in the pramipexole molecule and the DA receptor stimulation.
Background
Parkinson’s disease (PD) is the most common neurode-
generative movement disorder. The primary cause of
the disorder is the progressive loss of the pigmented
dopaminergic neurons in the substantia nigra pars com-
pacta (SNpc) accompanied by the appearance of intracy-
toplasmic inclusions known as Lewy bodies [1-3].
To date, the etiopathogenesis of nigral dopaminergic
neuron loss in PD is unknown. However, the presence
of ongoing oxidative stress as the result of compromised
antioxidant defence mechanisms and generation of radi-
cal oxygen species (ROS) in the SNpc of the parkinso-
nian brain are considered to be important Pathogenic
mechanisms [3,4]. ROS can react with cellular macro-
molecules through oxidation and cause the cells to
undergo dysfunction and eventually lead to necrosis or
apoptosis. The control of the redox environment of the
cell provides an additional regulation in the signal trans-
duction pathways which are redox sensitive. Therefore,
an effective anti-parkinsonian therapy should not only
alleviate the disease associated symptoms, but should
also stop the progressive dopaminergic cell death in the
SN.
Modification of the rate of PD progression is currently
a highly debated topic. Increased oxidative stress is
indeed thought to be involved in the nigral cell death
which is a well established peculiar neuropathological
feature of PD. These mechanisms have been proven in
vitro and in animal models, but their relevance in
humans remains speculative [5,6]. However, several
dopamine (DA) agonists of the DA D2-receptor family
(including D2 and D3 subtypes) have recently been
shown to possess neuroprotective properties in different
in vitro and in vivo experimental PD models [7,8]. At
cellular level, independent groups have demonstrated
decreased free radical production and an amelioration of
DA neuronal loss following DA agonist treatment
[9-17]. Interestingly, not all the neuroprotective effects
were clearly mediated by DA-receptor stimulation.
Pramipexole (2-amino-4,5,6,7-tetrahydro-6-propylami-
nobenzathiazole) is a non-ergot DA agonist that has
been successfully applied to the treatment of Parkinson’s
disease. Pramipexole exhibits a high affinity for the D2
and D3 DA receptor subtypes but little or no affinity for
the D1 receptor family. The neuroprotective effects eli-
cited by this drug have directly and/or indirectly been
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zation or induction of the antiapoptotic Bcl-2 family
[18-21]. In particular, Le et al., [18] reported that prami-
pexole protected DAergic MES 23.5 cell line against
DA, 6-OH-DA and hydrogen peroxide (H2O2)-induced
cytotoxicity possibly through antioxidant effects, and
such neuroprotection was independent from DA recep-
tor stimulation not being prevented by selective D2 or
D3 antagonists. Similar results were obtained by Fujta et
al., [20] and Uberti et al [22], who demonstrated that
pramipexole inhibited generation of H2O2-induced reac-
tive oxygen species in PC12 cells and SH-SY5Y neuro-
blastoma cells, respectively, in a DA receptor
independent way. Recent data also demonstrated neuro-
protection by pramipexole against b-amyloid ROS gen-
eration and toxicity [19,22].
Pramipexole exists as two isomers. The S(-) enantio-
mer is a potent D2/D3receptor agonist and is extensively
used in the management of PD. In contrast, the R(+)
enantiomer is virtually devoid of any of the DA agonist
effects. Very limited studies are available to characterize
the pharmacological spectrum of the R(+) enantiomer of
pramipexole [19,22-27].
Here we show that S(-) and R(+) pramipexole are
endowed with equipotent efficacy in preventing cell
death induced by H2O2 and act as mitochondria-tar-
geted antioxidants.
Results
Neuroprotection against H2O2
SH-SY5Y neuroblastoma cell lines were differentiated
with 10 μM all-trans retinoic acid for 1 week to acquire
a neuronal phenotype. Cells were then challenged with
1m MH 2O2 for 5 min then cells returned to fresh med-
ium for additional 24 h. H2O2 caused a reduction in cell
viability of about 70% in comparison with untreated
control cells (figure 1). As shown in figure 1A, treat-
ment of the cells with increasing concentrations of S(-)
or R(+) pramipexole dose-dependently prevented the
viability impairment induced by H2O2. The tested drugs
showed equipotent efficacy with calculated IC50 values
of 8.8 ± 0.9 μM and 9.2 ± 0.6 μM for S(-) and R(+) pra-
mipexole enantiomer, respectively. The neuroprotective
effects of both pramipexole enantiomers were not pre-
vented by preincubation of the cells with 10 μMp h e -
noxybenzamine (data not shown), 10 μM haloperidol or
10 μM (-) sulpiride (Figure 1B). Haloperidol and sulpir-
ide treatments did not induce cell viability modifications
(data not shown).
Inhibition of mitochondrial ROS generation
The effects of pramipexole and its R(+) enantiomer have
been studied in an experimental model of mitochondrial
ROS generation by video-ratec o n f o c a lm i c r o s c o p yi n
living neuronal cells. This model allows detection of
ROS levels specifically generated in mitochondria and is
based on the CM-DCF formation after laser light stimu-
lation [28-30]. Figure 2A, upper panel, shows the results
from a representative experiment. Mitochondrial ROS
generation was evaluated in cells after increasing expo-
sure to laser at different intensity. In a parallel experi-
ment (lower panels), cells were preincubated with
Vitamin E (2 μl/100 ml) for 30 min before the laser
excitation. Fluorescence emission intensity was calcu-
lated as average grey level value per pixel and corrected
for background. Data are reported in the graph reported
in Figure 2B. The results clearly show that Vitamin E
prevented laser-induced ROS generation in mitochon-
dria of differentiated SH-SY5Y neuronal cells.
Using the same experimental paradigm, we tested the
effects of different concentrations of S(-) and R(+) prami-
pexole in laser-induced mitochondria ROS generation.
As shown in figure 3, both S(-) and R(+) pramipexole
dose-dependently prevented laser-induced ROS genera-
tion in mitochondria of differentiated SH-SY5Y neuronal
cells. When calculated as inhibition of ROS generation
after 9% laser intensity, both drugs showed similar
potency with IC50 values of 0.91 ± 0.14 μMa n d0 . 8 5±
0.21 μM for S(-) and R(+) pramipexole enantiomer,
respectively. The prevention of mitochondrial ROS gen-
eration induced by both pramipexole enantiomers was
not affected by preincubation of the cells with 10 μM
phenoxybenzamine (data not shown), 10 μM haloperidol
or 10 μM (-) sulpiride (Figure 4). Haloperidol and sulpir-
ide treatments did not modify laser-induced increase in
ROS production (data not shown).
Discussion
Pramipexole exists as two stereoisomers. The S(-) enan-
tiomer is a potent D2/D3 receptor agonist and is exten-
sively used in the management of PD. In contrast, the R
(+) enantiomer is virtually devoid of any of the DA ago-
nist effects. A growing number of experimental data
indicate an antioxidant property of pramipexole enantio-
mers, evidenced by equal antioxidant efficacy toward
H2O2 and nitric oxide [24] and equipotent efficacy in
preventing viability impairment induced by H2O2 and
mithocondrial ROS generation (present results). We
found S(-) and R(+) pramipexole enantiomers relatively
weak H2O2 scavengers, with apparent IC50 values in the
low micromolar range. Our data are consistent with pre-
vious data showing neuroprotection elicited by the S(-)
and R(+) enantiomers against different neurotoxic
agents [9,22-27]. In our study, S(-) and R(+) pramipex-
ole enantiomer showed equipotent efficacy suggesting
that the neuroprotective effects against H2O2 in differ-
entiated SH-SY5Y neuroblastoma cells were DA recep-
tor independent.
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of action of pramipexole, several finding implicate the
permeability transition pore (PTP) as a possible target of
this drug [19,24,25]. Apart from binding to DA recep-
tors, pramipexole has in fact been shown to enter and
accumulate in mitochondria driven by the mitochondrial
membrane potential [24]. Targeting to mitochondria has
also been recently demonstrated by patch clamp studies
showing inhibition of PTP by pramipexole [25]. PTP
inhibition by pramipexole was further supported by
experimental data obtained in functional intact mito-
chondria showing that this drug abolished Ca
++-trig-
gered swelling [25]. By video-rate confocal microscopy
in living neuronal cells, we found that both S(-) and R
(+) pramipexole enantiomers prevented laser-induced
ROS generation in mitochondria of differentiated SH-
SY5Y neuronal cells. Interestingly, both pramipexole
enantiomers prevented mitochondrial ROS generation
with a potency about ten times higher then that elicited
for neuroprotection.
The apparent discrepancy between the different poten-
cies of pramipexole enantiomers in preventing mito-
chondrial ROS generation (about 0.9 μM) and inhibiting
H2O2-triggered viability impairment (about 8 μM) may
be related to the different experimental models. In fact,
H2O2 itself is not a radical but reacts with iron to form
hydroxyl radicals, the most reactive oxygen species.
Thus, in our experimental paradigm, ROS are generated
both intra- and extracellularly and causes apoptosis by
the induction of several intracellular converging
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Figure 1 Neuroprotective effects of pramipexole (PPX) enatiomers against H2O2-induced cell death. A) Differentiated SH-SY5Y cells were
exposed to different concentrations of S(-) PPX (gray bars) and R(+) PPX (black bars) for 1 h before being exposed to 1 mM H2O2 for 10 min.
Cell viability was evaluated 24 h after by MTT assay B) Cells were exposed to 50 μM μM S(-) PPX or R(+) PPX in the presence or absence of 10
μM haloperidol (H) or 10 μM (-) sulpiride (S). Data represent means ± SEM of at least three different experiments and are from three separate
cell preparations. *, p < 0.01 vs H2O2 alone values.
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and DNA damage. We hypothesize that accumulation of
promipexole enantiomers in the mitochondria [23,24]
may limit their scavenger properties to specific subcellu-
lar compartments. Although accumulation of pramipex-
ole into mitochondria has not been definitely
established, the high potency of these drugs in prevent-
ing mitochondrial ROS generation strongly suggest the
mitochondria as their primary site of action.
Conclusions
These results support the concept of both S(-) and R(+)
pramipexole enantiomers as mitochondria-targeted anti-
oxidants and suggest that the antioxidant, neuroprotec-
tive activity of these drugs is independent of both the
chiral 6-propylamino group in the pramipexole molecule
and the DA receptor stimulation.
Methods
Cell culture
The human neuroblastoma cell line SH-SY5Y was routi-
nely cultured in Ham’s F12 and Dulbecco modified
Eagle’s medium (DMEM) in a ratio of 1:1, supplemented
with 10% (v/v) foetal calf serum, 2 mM glutamine, 50
μg/ml penicillin, and 100 μg/ml streptomycin and kept
at 37°C in humidified 5% CO2/95% atmosphere. For dif-
ferentiation, cultured cells were treated for one week
with 10 μM all trans retinoic acid. To obtain reproduci-
ble results, SH-SY5Y cells ranging from passage 18 to
passage 25 were used for all the experiments.
Drug treatment
S(-) and R(+) pramipexole were dissolved in water and
added to the culture media 1 h before H2O2 pulse or
laser light stimulation. IC50 values for S(-) and R(+) pra-
mipexole enantiomer were calculated using at least 5
data points. Haloperidol and sulpiride were added to the
culture media 1 h before pramipexole. Vitamin E (2 ng/
100 μl) was added to the culture media 30 min before
the laser excitation. All drugs were from Sigma. S(-) and
R(+) pramipexole were kindly supplied by Boehringer
Ingelheim GmbH, Germany.
Evaluation of cell viability
Cell viability was measured by quantitative colorimetric
assay with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide), showing the mitochondrial
activity of living cells. Differentiated SH-SY5Y neuronal
Figure 2 Detection of mitochondrial ROS generation. A) Upper panel. Representative pictures from cells exposed to increasing laser intensity,
as indicated. CM-DCF fluorescence intensity (green) was selectively recorded in mitochondria (red). Lower panel. Cells were preincubated with
Vitamin E (2 ng/100 μl) for 30 min before the laser excitation (white bars in panel B). Fluorescence emission intensity was calculated as average
grey level value per pixel and corrected for background. Bars in panel B represent the means ± SEM of at least three different experiments and
are from three separate cell preparations. *, p < 0.01 vs the corresponding control values.
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Page 4 of 6cells in 96-well plates were challenged with H2O2 for 5
min, then 500 μg/ml MTT was added in each well and
cells were incubated at 37°C for additional 3 h. MTT
was removed, and cells were lysed with dimethyl sulfox-
ide. The absorbance at 595 nm was measured using a
Bio-Rad 3350 microplate reader. Control cells were trea-
ted in the same way without H2O2,a n dt h ev a l u e so f
different absorbances were expressed as a percentage of
control. All the drugs and reagents concentrations are
to be considered as final concentrations.
Reactive oxygen species detection
SH-SY5Y neuroblastoma cells were first differentiated in
neuronal-like phenotype by treatment with retinoic acid
for 7 days; then, according to Koopman et al. [28], cells
were loaded with 5-choloromethyl-2’,7’-dichlorodihydro-
fluorescein (CM-H2DCF) and its oxidative conversion
into CM-DCF was monitored by video-rate confocal
microscopy and real-time image averaging after increas-
ing laser intensities. For mitochondria localization, cells
were also loaded with Mitotracker Deep Red. Cells were
then excited at increasing laser intensity and CM-DCF
fluorescence intensity was selectively recorded in mito-
chondria. Fluorescence emission intensity was calculated
as average grey level value per pixel and corrected for
background.
Statistical evaluation
Results were given as mean ± standard error mean
values. Statistical significance of differences was deter-
mined by one way ANOVA, followed by Bonferroni’s
multiple comparison test as post-hoc analysis. A prob-
ability of less than 0.05 was considered as a significant
difference.
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Figure 3 Inhibition of mitochondrial ROS generation by
pramipexole (PPX) enantiomers. Cells were exposed to different
concentrations, as indicated in the bottom, of S(-) PPX (upper panel)
and R(+) PPX (lower panel) for 1 h before being exposed to laser.
Mitochondrial ROS generation was evaluated as in figure 2. Data
represent means ± SEM of at least three different experiments and
are from three separate cell preparations. *, p < 0.05 and **, p <
0.001 vs the corresponding control values (black bars).
Figure 4 Lack of effect of DA receptor antagonists on the
inhibition of mitochondrial ROS generation induced by
pramipexole (PPX) enantiomers. Cells were exposed to 10 μM S(-)
PPX (gray bars) and R(+) PPX (white bars) for 1 h in the absence or
presence of 10 μM haloperidol (H) or 10 μM (-) sulpiride (S) before
being exposed to laser. Mitochondrial ROS generation was
evaluated as in figure 2. Data represent means ± SEM of at least
three different experiments and are from three separate cell
preparations. *, p < 0.01 vs the corresponding control values (black
bars).
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